Multi Omics Data Integration to predict the M. tuberculosis Bedaquiline Resistance Phenotype from the Genotype
A 7-laboratory study to calibrate antimicrobial susceptibility testing methods and breakpoints against EUCAST reference standards for bedaquiline, clofazimine, levofloxacin, and linezolid
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors (RespiriTB).
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors (RespiriTB).
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors (RespiriTB).
Protocol, rationale and design of BE-PEOPLE (Bedaquiline enhanced exposure prophylaxis for LEprosy in the Comoros): a cluster randomized trial on effectiveness of rifampicin and bedaquiline as post-exposure prophylaxis of leprosy contacts
Validation of bedaquiline phenotypic drug susceptibility testing methods and breakpoints: a multilaboratory, multicountry study
Linking in vitro intrinsic dissolution rate and thermodynamic solubility with pharmacokinetic profiles of bedaquiline long-acting aqueous microsuspensions in rats
A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant